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bridization signal present in the DNA of all 31 patients. Of 
these SNP probes, 284 corresponded to 3 or more copies and 
147 corresponded to 1 or 0 copies. Several cancer-associated 
genes were amplified in all patients. Conversely, several 
genes supposed to oppose cancer development were pres-
ent as single copy.  Conclusions: These data suggest that a 
set of 431 CNVs could be associated with the disease. This set 
could be useful for early diagnosis.  © 2013 S. Karger AG, Basel 
 Introduction 
 Pancreatic cancer represents 3% of all new cases of 
cancer but leads to 5% of all cancer deaths  [1] . In the gen-
eral population, it carries a lifetime risk of approximately 
1%  [2] . Environmental factors such as cigarette smoking 
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 Abstract 
 Objectives: The rapid fatality of pancreatic cancer is, in large 
part, the result of diagnosis at an advanced stage in the ma-
jority of patients. Identification of individuals at risk of devel-
oping pancreatic adenocarcinoma would be useful to im-
prove the prognosis of this disease. There is presently no 
biological or genetic indicator allowing the detection of pa-
tients at risk. Our main goal was to identify copy number 
variants (CNVs) common to all patients with sporadic pan-
creatic cancer.  Methods: We analyzed gene CNVs in leuko-
cyte DNA from 31 patients with sporadic pancreatic adeno-
carcinoma and from 93 matched controls. Genotyping was 
performed with the use of the GeneChip Human Mapping 
500K Array Set (Affymetrix).  Results: We identified 431 single 
nucleotide polymorphism (SNP) probes with abnormal hy-
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 [3] or diseases such as diabetes  [4] , obesity  [5] or chronic 
pancreatitis  [6] predispose pancreatic cancer. Familial 
factors are also involved in the susceptibility to pancre-
atic cancer  [7] . The lifetime risk of pancreatic cancer is 
4.7% for first-degree relatives of pancreatic cancer cases 
and increases with each family member who is affected. 
Pancreatic cancer can also be inherited as part of a multi-
cancer syndrome such as that associated with BRCA2 
mutations  [8] , Peutz-Jeghers syndrome  [9] , and familial 
atypical mole and melanome syndrome  [10] . In these cas-
es, the family pedigree shows evidence of other cancers 
such as breast or intestinal tumors, or melanomas, in ad-
dition to pancreatic tumors. However, the vast majority 
of pancreatic cancers are sporadic. The molecular mecha-
nisms by which they occur involve alterations in somatic 
gene expression, which include  KRAS2,  BRCA2 and  TP53 
mutations, telomere shortening, p21 and cyclin D1 up-
regulations, inactivation of p16 INK4 /CDKN2A and DPC4/
SMAD4, and expression of proliferation antigens  [11] . 
The discovery of a gene (or genes), which causes sporad-
ic pancreatic adenocarcinoma when altered in the germ-
line, would provide important insight into the biology of 
the disease. In addition, the altered gene would be a useful 
marker allowing early detection of the disease. Therefore, 
the identification of such gene(s) is a priority for scientists 
and physicians who hope to change the dismal prognosis 
of this cancer.
 Recently, several studies have discovered an abun-
dance of submicroscopic copy number variations (CNVs) 
of DNA segments ranging from kilobases to megabases 
in size  [12] . Deletions, insertions, duplications and com-
plex multisite variants, collectively termed ‘copy number 
variations’, were found in all humans  [13] . New array-
based technologies can detect differences in DNA copy 
number at much higher resolution than cytogenetic 
methods  [14] , and hence, might reveal previously un-
identified spontaneous mutations. In the last years, ge-
nome analysis provided a powerful approach to test for 
evidence of genetic variations within and between geo-
graphical regions and local populations  [15] . In a recent 
work, Chen et al.  [16] reported that whereas the overall 
CNV frequencies are similar between populations, their 
distribution is highly specific to the population of origin. 
Recently, Huang et al.  [17] reported that pancreatic can-
cer risk is significantly associated with a CNV at 6q13 
(CNVR2966.1) through a long-range transcriptional reg-
ulation of  CDKN2B that shows lower transcriptional lev-
els in pancreatic tissues of individuals with low copy 
number (1 or 0). Furthermore, in 2009, Amundadottir
et al.  [18] identified a single nucleotide polymorphism 
(SNP) that maps the first intron of the ABO blood group 
gene which is significantly associated with pancreatic 
cancer, suggesting that people with blood group O may 
have a lower risk than those with groups A or B. How-
ever, the involvement of this SNP in the susceptibility to 
pancreatic cancer remains to be established  [18] .
 In this work, we used the Affymetrix platform (Af-
fymetrix Inc., Santa Clara, Calif., USA) to genotype 
500,000 unique SNPs. The median physical distance be-
tween SNPs is 2.5 kb and the average distance between 
SNPs is 5.8 kb. These techniques have shown an abun-
dance of CNVs in humans  [19] , and the same methods 
have been used to find de novo chromosome aberrations 
below the resolution of microscopy in children with men-
tal retardation and dysmorphic features  [20, 21] , includ-
ing patients with syndromic forms of autism  [22] . We 
have performed high-resolution genomic microarray 
analysis on 31 patients with sporadic pancreatic adeno-
carcinoma to determine the rate of de novo CNV and 
found that patients affected with this disease show sev-
eral common CNVs that are absent in individuals with-
out apparent disease.
 Materials and Methods 
 Acquisition of Samples 
 The study was approved by the appropriate institutional review 
board at each participating site. Written informed consent was ob-
tained from all participants. Between March 13 and June 26, 2012, 
we prospectively collected 31 DNA samples from peripheral leu-
kocytes from patients with a diagnosis of sporadic pancreatic ad-
enocarcinoma. Patients with a familial pancreatic cancer history 
were excluded. Diagnosis of adenocarcinoma was confirmed by 
histologic analysis. All clinical information for every enrolled pa-
tient was entered in an anonymous and coded format. All DNA 
samples were of sufficient quality to be genotyped. Twenty-four 
patients were European (20 from Palermo and 4 from Barcelona) 
and 7 were Japanese (as self-reported in the presence of the physi-
cian). Of these patients, 18 were men and 13 were women, with a 
mean age of 62 years. Control DNAs from individuals without can-
cer, matched by sex and ethnic origin, were used. For each patient 
with pancreatic adenocarcinoma, we randomly selected 3 individ-
uals with no history of cancer as controls. As a reference set, we 
used the HapMap database  [23] .
 CNV Analysis 
 DNA was extracted from whole blood of patients with pancre-
atic adenocarconoma using the QIAamp mini kit (Qiagen, 
Chatsworth, Calif., USA), according to the manufacturer’s instruc-
tions. The DNA yields and purity were determined spectrophoto-
metrically by measuring the absorbance of aliquots at 260 and 280 
nm. DNA was prepared for microarray hybridization using the 
Affymetrix GeneChips Human Mapping 500K Set (Affymetrix) as 
previously described by Pugh et al.  [24] . The raw images were an-
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alyzed using the GeneChip operating software (GCOS version 
1.4.1) and GTYPE (version 4.1) software (Affymetrix). We exclud-
ed those samples with a genotype call rate <93%. To assess copy 
number alterations, we used the CNAT (version 4.0.1) software. 
We set the genomic smoothing at 0.01 Mb and kept the default 
parameters for the other variables. Copy number estimates were 
done using data from 172 HapMap samples as a reference. Chro-
mosome X was not analyzed to avoid gender-related complica-
tions. The reproducibility of the method was assessed by analyzing 
6 DNAs from patients with pancreatic adenocarcinoma in dupli-
cate and we found that >96% of CNVs were confirmed in both as-
says.
 Data Analysis 
 Using the SAS software and ad hoc programs, individual tables 
generated by CNAT (CNAT version 4.0.1) were merged and SNPs 
were ranked according to their copy number value. Two lists con-
taining the SNPs with copy number gains (3 or 4 copies) or losses 
(1 or 0 copies) were generated. In order to keep all CNVs, even 
single SNPs, and at the same time to avoid false-positive changes 
due to random noise in signal intensity, we only kept the SNPs with 
the same condition, i.e. gain or loss, in all 31 patients. Thereafter, 
selected SNP probes were merged with their respective gene an-
notations and physical positions according to the National Center 
for Biotechnology Information  human genome sequence (Build 
36.1, March 2006) using the NetAffx web server (Affymetrix).
 Results 
 CNVs in Patients with Pancreatic Adenocarcinoma 
 The main goal of this work was to identify CNVs 
shared by patients with sporadic pancreatic adenocarci-
noma to be used as markers of the disease and to iden-
tify the perturbations in intracellular pathways that 
could lead to the disease. The analysis revealed that the 
number of abnormal SNP probe hybridization signals, 
relative to the HapMap set, ranged from 22,284 to 56,664 
(median value 33,621) in patients with sporadic pancre-
atic cancer. Several of them were common to all patients. 
When looking at how the number of common SNPs 
with an abnormal signal evolved with the number of pa-
tients included in the study, we observed a sharp de-
crease from 35,490 to 3,371 upon inclusion of the first 6 
patients, then a much slower decrease to 431 when the 
number of patients was increased to 31 ( fig. 1 ). We chose 
to work with the set defined by the 31 patients, although 
including more patients might allow us to select a small-
er set of common SNP probes. Data from the 7 Japanese 
patients did not influence the results (data not shown) 
suggesting that the set of SNP probe variants common 
to all patients does not reflect their belonging to a par-
ticular ethnic group. To our knowledge, the only feature 
that the 31 patients have in common is that they present 
pancreatic adenocarcinoma, suggesting that the set of 
common CNVs reveals a predisposition to this disease. 
The set included 431 probes, of which 284 were found 
amplified (3 copies or more; online suppl. table 1; see 
www.karger.com/doi/10.1159/000354737 for all online 
suppl. material) and 147 showed 1 copy or none (online 
suppl. table  2). These probes corresponded to an in-
creased number of alleles for 85 genes and to an allele 
loss or a deletion for 72 genes ( table 1 ; online suppl. ta-
ble 3). In a restricted number of cases, probes located to 
the same gene appeared with a different copy number 
for the same patient.
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 Fig. 1. Common CNVs in 31 patients with 
pancreatic adenocarcinoma. The number 
of SNP probes with abnormal signal hy-
bridization (copy number difference of 2) 
that were common between patients is pre-
sented. 
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 Genes Whose Allele Number Is Altered in Patients 
with Pancreatic Adenocarcinoma 
 Identification of genes implicated in the CNVs of pa-
tients with pancreatic adenocarcinoma could be useful 
for diagnostic purposes, to understand the physiopathol-
ogy of this cancer and, eventually, to target these genes in 
therapeutic strategies. For diagnostic purposes, altered 
DNA dosage that affects regions containing genes or in-
tergenic regions is indifferent. By contrast, to get insight 
into the pathophysiology of the disease, only CNVs that 
affect genes are of interest. We found that several genes 
encoding cancer-associated products such as  CDC14B, 
 CENPE,  EIF2S2,  FGF20,  FZD10, GTF3C3, KLHL1, 
NOTCH3, RAB21, TULP3, VSNL1 and  ZWINT were am-
plified in all 31 patients with pancreatic cancer included 
in this study. In addition, 15 genes encoding putative pro-
teins with unknown function were also found amplified 
in all 31 patients. The products of other known genes 
found amplified are involved in intracellular signaling, 
cell-to-cell or cell-to-extracellular matrix interactions. 
They also included structural proteins, secretory pro-
teins, receptors, metabolic enzymes, enzymes involved in 
posttranslational modifications, transcriptional factors 
or nuclear proteins, but their direct relationship with car-
cinogenesis is not formally established. On the other 
hand, 10 genes supposed to act against cancer develop-
ment  (ASH1L, CD9, GRB14, IER3, LPXN, MAP3K7, 
MDC1, MINK1, SGPL1 and  VRK1) were present as single 
copy in the genome of all 31 patients with pancreatic ad-
enocarcinoma. Several genes encoding intracellular sig-
naling factors, structural proteins, secretory proteins, re-
ceptors, metabolic enzymes, or transcriptional factors 
also showed allele loss. Finally, 10 genes with unknown 
function showed allele loss in all patients. The role of 
these proteins in cancer remains to be established.
 It is also important to note that several important 
genes involved in cancer were amplified in 30 of 31 pa-
tients, such as  BMP1, EGFL11, FLT4, FOSB, KIT, 
MAP4K4, MYB, PDGFRA and  TGFA, and 30 of 31 pa-
tients had lost one allele of the Myc inhibitor  PAK2. Fi-
nally,  ARRB2 was deleted in 29 of 31 patients and  AKT3 
and  KRAS were amplified in 28 of 31 patients. The list of 
genes with an abnormal copy number is presented in on-
line supplementary table 4.
 Specificity of the Repertoire of CNVs in Patients with 
Sporadic Pancreatic Cancer 
 Ninety-three individuals apparently free of any dis-
ease, matched with pancreatic cancer patients, were used 
as controls. They were randomly divided into 3 groups of 
31 individuals and their DNAs were investigated for the 
presence of common SNP probes with abnormal hybrid-
ization signal. To our surprise, finding common CNVs 
among these individuals was exceptional, in strong con-
trast with data obtained in patients developing pancre-
atic adenocarcinoma. The highest score observed was 21 
SNP probes common to 31 controls. When two thirds of 
DNA samples were randomly replaced in each group by 
samples from the other 2 groups, results were very similar 
(data not shown). The next step was to look whether the 
set of CNVs common to all patients with sporadic pan-
creatic cancer could be observed in the DNA of the 93 
individuals used as controls. To this end, the SNPs from 
the selected set of 431 probes were analyzed in each con-
trol patient. None of them showed a similar profile. In 
fact, the highest number of abnormal signals in common 
Table 1.  Genes that show CNV gain or loss in all 31 patients with pancreatic adenocarcinoma
CNV gain ABCA13, ACVR1C, ADRA2C, AGMAT, ALDH1L1, ALS2CR12, ASIP, ATXN2L, C11orf39, C13orf28, C4orf23, 
C5orf30, C9orf139, C9orf21, CAND1, CCDC37, CDC14B, CENPE, CHD9, CSMD2, CTBP1, CXCL14, DACH1, DLC1, 
EIF2S2, EMB, FAM135B, FCHO1, FGF20, FLJ35424, FLJ38723, FPGT, FUT7, FZD10, GNLY, GPC5, GPC6, GPX7, 
GTF3C3, HABP4, HCN1, HNT, IMMP2L, IRX1, KCTD8, KLF15, KLHL1, KPNA1, LEPREL1, LOC153328, 
LOC154907, LOC340069, LRFN2, LRP1B, LRRN3, MAP1S, MGC21675, MSR1, N4BP3, NAT8L, NBPF11, NDST1, 
NLF2, NOTCH3, PAPPA2, PCDH9, PRDM16, RAB21, RPS14, SFTPB, SOX1, SYT1, TMEM19, TULP3, TYW1, UPP1, 
VAC14, VSNL1, WDR78, WHSC2, ZCCHC11, ZNF134, ZNF211, ZSCAN4, ZWINT
CNV loss ABCF1, AIG1, ALDH2, ASH1L, C10orf59, C20orf11, C6orf134, C6orf136, C9orf86, CBARA1, CD9, CENTG2, CHRNE, 
CYP2A13, DDR1, DHH, DHX16, DNAJB12, DNMT1, DUOX2, DUOXA1, ERAF, FAM55C, FBXO2, FBXO44, FIGN, 
FLJ20294, FLOT1, GBE1, GCS1, GMCL1, GNL1, GRB14, GRM3, HLA-E, HPGD, IER3, JSRP1, KIAA0922, KIAA1712, 
KLHL14, LMBR1L, LOC90826, LPXN, MAP3K7, MDC1, MINK1, MRPS18B, MYO9B, NR4A3, NRM, OAZ1, OR5B21, 
OSR2, PFKL, PLD2, PPP1R10, PRR3, RAMP1, RAP1GDS1, RHEBL1, RHOU, SGPL1, SH3BP4, SNX27, SOX6, TLR2, 
TUBB, VRK1, VWF, ZCCHC7, ZEB2
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with the 431 SNPs typical of patients found in a control 
was only 24 (approximately 5%) as shown in online sup-
plementary table  5. These data suggest that the set of 
CNVs detected in patients with sporadic pancreatic ade-
nocarcinoma is powerfully associated with the disease.
 Discussion 
 Pancreatic adenocarcinoma may be sporadic or of fa-
milial origin, including patients with a multi-cancer syn-
drome. To our present knowledge, sporadic cases repre-
sent 90% of all pancreatic cancers. Sporadic pancreatic 
adenocarcinoma development may be associated with 
environmental factors or with some pancreatic diseases 
 [25] but, in this context, predisposition due to a peculiar 
genetic background is also suspected. In this work, we re-
port that patients developing sporadic pancreatic adeno-
carcinoma have in common a series of DNA structural 
variations that are not observed in control patients. Iden-
tification of this CNV set may be used for the diagnosis of 
an individual with a genetic predisposition to develop 
sporadic pancreatic cancer, for understanding the phys-
iopathology of this disease and also to target these genes 
in a preventive strategy.
 Pancreatic cancer has one of the most terrible progno-
ses. One of the reasons is that diagnosis occurs when al-
most all therapeutic strategies are ineffective. In this con-
text, the possibility to identify patients with a predisposi-
tion to the disease would certainly be helpful. In a previous 
study, Lucito et al.  [26] reported that patients with a fa-
milial history of pancreatic cancer showed a total of 56 
unique germline genomic regions with CNVs that were 
not present in controls, including 31 amplifications and 
25 deletions. Interestingly, when we compared the com-
mon genes presumably involved in the development of 
familial  [26] or sporadic pancreatic cancer (this work), we 
found no common genes suggesting that the develop-
ment of these cancers occurs through different pathways. 
This observation is in agreement with the fact that envi-
ronmental factors are associated with sporadic cancer but 
have little impact, if any, on the occurrence of the familial 
disease  [11] . An attractive hypothesis is that genomic al-
terations associated with inherited pancreatic cancer 
have sufficient penetrance to trigger the disease, whereas 
alterations associated with sporadic pancreatic cancer re-
quire the additional influence of environmental factors to 
allow cancer development.
 It is known that cancer occurs in about 20% of indi-
viduals. If predisposition to cancer is the consequence of 
a series of inherited genetic abnormalities, in a group of 
individuals chosen at random, the corresponding set of 
genetic abnormalities should be shared by an equivalent 
percentage of individuals. This was not the case in the set 
of the 93 control DNAs that we analyzed. We did not find 
any subset of CNVs in such proportion, suggesting that 
there is no genetic predisposition to cancer but that more 
specific sets of genetic abnormalities will predispose to 
cancers of specific organs; the set of 431 SNP probes as-
sociated with pancreatic cancer identified in this study is 
an example of such specificity.
 Mechanistically, how might CNVs be involved in 
complex disease? When deletions or duplications are 
present within a gene or its regulatory regions, they will 
probably generate an imbalance in the corresponding 
RNA level and consequently in the level of the encoded 
product. For genes and pathways in which the amount of 
a functional product is critical, it seems likely that CNVs 
could account for individual variations in the susceptibil-
ity to the disease  [27] . In this paper, we report that sev-
eral genes involved in cancer development show specific 
structural variations. We also identified several candidate 
genes not yet associated with pancreatic cancer develop-
ment. These genes will be further studied as candidates 
that could favor cancer development.
 In summary, we report that a restricted set of SNP 
probes with abnormal hybridization signals is found in 
germline DNA of all patients with sporadic pancreatic ad-
enocarcinoma included in our study, but not in unaffect-
ed patients. This set might be used as a diagnostic tool.
 Disclosure Statement 
 The authors declare no conflict of interest.
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